|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
2
|
|
pubmed:dateCreated |
1996-10-29
|
|
pubmed:abstractText |
Fluvoxamine is a selective serotonin reuptake inhibitor used widely in the treatment of depression and other psychiatric diseases, but little is known about the specific isozymes involved in its metabolism. This study investigated the relationship between fluvoxamine disposition and the polymorphic CYP2D6 and the polycyclic aromatic hydrocarbon (as contained in cigarette smoke) inducible CYP1A2.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
AIM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Aug
|
|
pubmed:issn |
0009-9236
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
60
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
183-90
|
|
pubmed:dateRevised |
2006-11-15
|
|
pubmed:meshHeading |
pubmed-meshheading:8823236-Adrenergic Agents,
pubmed-meshheading:8823236-Adult,
pubmed-meshheading:8823236-Caffeine,
pubmed-meshheading:8823236-Central Nervous System Stimulants,
pubmed-meshheading:8823236-Chromatography, High Pressure Liquid,
pubmed-meshheading:8823236-Cytochrome P-450 CYP1A2,
pubmed-meshheading:8823236-Cytochrome P-450 CYP2D6,
pubmed-meshheading:8823236-Debrisoquin,
pubmed-meshheading:8823236-Female,
pubmed-meshheading:8823236-Fluvoxamine,
pubmed-meshheading:8823236-Humans,
pubmed-meshheading:8823236-Male,
pubmed-meshheading:8823236-Middle Aged,
pubmed-meshheading:8823236-Reference Values,
pubmed-meshheading:8823236-Serotonin Uptake Inhibitors,
pubmed-meshheading:8823236-Smoking
|
|
pubmed:year |
1996
|
|
pubmed:articleTitle |
Disposition of fluvoxamine in humans is determined by the polymorphic CYP2D6 and also by the CYP1A2 activity.
|
|
pubmed:affiliation |
Department of Medical Laboratory Sciences and Technology, Huddinge Hospital, Sweden.
|
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|
